Atopic Dermatitis
1,087
123
174
647
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
245 trials with published results (23%)
Research Maturity
647 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.5%
81 terminated out of 1087 trials
88.9%
+2.3% vs benchmark
23%
246 trials in Phase 3/4
38%
245 of 647 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 647 completed trials
Clinical Trials (1087)
Cardamom and Topical Roseomonas in Atopic Dermatitis
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
A Clinical Study to Assess the Safety and Effectiveness of Test Products in Mild to Moderate Atopic Dermatitis (AD) Patients.
Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
A Study Evaluating APG777 in Atopic Dermatitis
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema